Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer

A clinical position statement

Frederik A. Verburg, Markus Luster, Cristina Cupini, Luca Chiovato, Leonidas Duntas, Rossella Elisei, Ulla Feldt-Rasmussen, Harald Rimmele, Ettore Seregni, Johannes W A Smit, Christian Theimer, Luca Giovanella

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Background: Even though the presence of antithyroglobulin antibodies (TgAbs) represents a significant problem in the follow-up of patients with differentiated thyroid cancer (DTC), the current guidelines on the management of DTC that have been published in recent years contain no text concerning the methods to be used for detecting such antibody-related interference in thyroglobulin (Tg) measurement or how to manage TgAb-positive patients in whom Tg cannot be used reliably as a tumor marker. Aim: An international group of experts from the European Thyroid Association Cancer Research Network who are involved in the care of DTC patients met twice to form a consensus opinion on how to proceed with treatment and follow-up in TgAb-positive DTC patients based on the available evidence in the literature. Here we will report on the consensus opinions that were reached regarding technical and clinical issues. Results: This clinical opinion article provides an overview of the available evidence and the resulting consensus recommendations. The current literature does not provide sufficient data for giving evidence-based answers to many questions arising in the care of TgAb-positive DTC patients. Where insufficient evidence was available, a thorough discussion by a group of physician- scientists, all of whom have a distinguished track record in thyroid cancer care, was held to arrive at a consensus expert opinion. The questions and answers discussed were then summarized into an algorithm for the management of TgAb-positive patients. Conclusion: We were able to define 26 consensus expert recommendations and a resulting algorithm for the care of TgAb-positive DTC patients.

Original languageEnglish
Pages (from-to)1211-1225
Number of pages15
JournalThyroid
Volume23
Issue number10
DOIs
Publication statusPublished - Oct 1 2013

Fingerprint

Thyroglobulin
Thyroid Neoplasms
Antibodies
Expert Testimony
Tumor Biomarkers
Guidelines
Physicians
Research
Neoplasms

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer : A clinical position statement. / Verburg, Frederik A.; Luster, Markus; Cupini, Cristina; Chiovato, Luca; Duntas, Leonidas; Elisei, Rossella; Feldt-Rasmussen, Ulla; Rimmele, Harald; Seregni, Ettore; Smit, Johannes W A; Theimer, Christian; Giovanella, Luca.

In: Thyroid, Vol. 23, No. 10, 01.10.2013, p. 1211-1225.

Research output: Contribution to journalArticle

Verburg, FA, Luster, M, Cupini, C, Chiovato, L, Duntas, L, Elisei, R, Feldt-Rasmussen, U, Rimmele, H, Seregni, E, Smit, JWA, Theimer, C & Giovanella, L 2013, 'Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: A clinical position statement', Thyroid, vol. 23, no. 10, pp. 1211-1225. https://doi.org/10.1089/thy.2012.0606
Verburg, Frederik A. ; Luster, Markus ; Cupini, Cristina ; Chiovato, Luca ; Duntas, Leonidas ; Elisei, Rossella ; Feldt-Rasmussen, Ulla ; Rimmele, Harald ; Seregni, Ettore ; Smit, Johannes W A ; Theimer, Christian ; Giovanella, Luca. / Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer : A clinical position statement. In: Thyroid. 2013 ; Vol. 23, No. 10. pp. 1211-1225.
@article{6bd9a2e3a7034b4da6c197ab5a4b6f5e,
title = "Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: A clinical position statement",
abstract = "Background: Even though the presence of antithyroglobulin antibodies (TgAbs) represents a significant problem in the follow-up of patients with differentiated thyroid cancer (DTC), the current guidelines on the management of DTC that have been published in recent years contain no text concerning the methods to be used for detecting such antibody-related interference in thyroglobulin (Tg) measurement or how to manage TgAb-positive patients in whom Tg cannot be used reliably as a tumor marker. Aim: An international group of experts from the European Thyroid Association Cancer Research Network who are involved in the care of DTC patients met twice to form a consensus opinion on how to proceed with treatment and follow-up in TgAb-positive DTC patients based on the available evidence in the literature. Here we will report on the consensus opinions that were reached regarding technical and clinical issues. Results: This clinical opinion article provides an overview of the available evidence and the resulting consensus recommendations. The current literature does not provide sufficient data for giving evidence-based answers to many questions arising in the care of TgAb-positive DTC patients. Where insufficient evidence was available, a thorough discussion by a group of physician- scientists, all of whom have a distinguished track record in thyroid cancer care, was held to arrive at a consensus expert opinion. The questions and answers discussed were then summarized into an algorithm for the management of TgAb-positive patients. Conclusion: We were able to define 26 consensus expert recommendations and a resulting algorithm for the care of TgAb-positive DTC patients.",
author = "Verburg, {Frederik A.} and Markus Luster and Cristina Cupini and Luca Chiovato and Leonidas Duntas and Rossella Elisei and Ulla Feldt-Rasmussen and Harald Rimmele and Ettore Seregni and Smit, {Johannes W A} and Christian Theimer and Luca Giovanella",
year = "2013",
month = "10",
day = "1",
doi = "10.1089/thy.2012.0606",
language = "English",
volume = "23",
pages = "1211--1225",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "10",

}

TY - JOUR

T1 - Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer

T2 - A clinical position statement

AU - Verburg, Frederik A.

AU - Luster, Markus

AU - Cupini, Cristina

AU - Chiovato, Luca

AU - Duntas, Leonidas

AU - Elisei, Rossella

AU - Feldt-Rasmussen, Ulla

AU - Rimmele, Harald

AU - Seregni, Ettore

AU - Smit, Johannes W A

AU - Theimer, Christian

AU - Giovanella, Luca

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Background: Even though the presence of antithyroglobulin antibodies (TgAbs) represents a significant problem in the follow-up of patients with differentiated thyroid cancer (DTC), the current guidelines on the management of DTC that have been published in recent years contain no text concerning the methods to be used for detecting such antibody-related interference in thyroglobulin (Tg) measurement or how to manage TgAb-positive patients in whom Tg cannot be used reliably as a tumor marker. Aim: An international group of experts from the European Thyroid Association Cancer Research Network who are involved in the care of DTC patients met twice to form a consensus opinion on how to proceed with treatment and follow-up in TgAb-positive DTC patients based on the available evidence in the literature. Here we will report on the consensus opinions that were reached regarding technical and clinical issues. Results: This clinical opinion article provides an overview of the available evidence and the resulting consensus recommendations. The current literature does not provide sufficient data for giving evidence-based answers to many questions arising in the care of TgAb-positive DTC patients. Where insufficient evidence was available, a thorough discussion by a group of physician- scientists, all of whom have a distinguished track record in thyroid cancer care, was held to arrive at a consensus expert opinion. The questions and answers discussed were then summarized into an algorithm for the management of TgAb-positive patients. Conclusion: We were able to define 26 consensus expert recommendations and a resulting algorithm for the care of TgAb-positive DTC patients.

AB - Background: Even though the presence of antithyroglobulin antibodies (TgAbs) represents a significant problem in the follow-up of patients with differentiated thyroid cancer (DTC), the current guidelines on the management of DTC that have been published in recent years contain no text concerning the methods to be used for detecting such antibody-related interference in thyroglobulin (Tg) measurement or how to manage TgAb-positive patients in whom Tg cannot be used reliably as a tumor marker. Aim: An international group of experts from the European Thyroid Association Cancer Research Network who are involved in the care of DTC patients met twice to form a consensus opinion on how to proceed with treatment and follow-up in TgAb-positive DTC patients based on the available evidence in the literature. Here we will report on the consensus opinions that were reached regarding technical and clinical issues. Results: This clinical opinion article provides an overview of the available evidence and the resulting consensus recommendations. The current literature does not provide sufficient data for giving evidence-based answers to many questions arising in the care of TgAb-positive DTC patients. Where insufficient evidence was available, a thorough discussion by a group of physician- scientists, all of whom have a distinguished track record in thyroid cancer care, was held to arrive at a consensus expert opinion. The questions and answers discussed were then summarized into an algorithm for the management of TgAb-positive patients. Conclusion: We were able to define 26 consensus expert recommendations and a resulting algorithm for the care of TgAb-positive DTC patients.

UR - http://www.scopus.com/inward/record.url?scp=84884411947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884411947&partnerID=8YFLogxK

U2 - 10.1089/thy.2012.0606

DO - 10.1089/thy.2012.0606

M3 - Article

VL - 23

SP - 1211

EP - 1225

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 10

ER -